Securing reimbursement approval from the Health Service Executive (HSE) is one of the most critical Hurdles facing pharmaceutical companies in Ireland today. With the National Centre for Pharmacoeconomics (NCPE) enforcing a rigorous assessment process, demonstrating pure clinical efficacy is no longer enough to guarantee success. Healthcare technology assessors now demand concrete proof of real-world value. This whitepaper explores how advanced choice-based survey methodologies are revolutionizing pharmaceutical pricing, giving commercial teams the precise, quantified evidence needed to navigate the complex Irish reimbursement landscape.
The report details why traditional market research falls short when trying to satisfy the NCPE’s core evaluation pillars. Instead of relying on static surveys, Choice-Based Conjoint (CBC) analysis forces stakeholders – including patients, physicians, and payers – to make realistic trade-offs between competing product attributes like dosing frequency, side effect profiles, administration methods, and costs. The paper demonstrates how this data feeds directly into robust cost-effectiveness models and budget impact assessments, providing health technology assessors with defensible projections of actual real-world market uptake and patient adherence.
Crucially, this analysis advocates for a strategy that looks beyond physician-only research to actively integrate the patient voice. In chronic therapeutic areas like COPD, asthma, and diabetes—which affect hundreds of thousands of individuals across Ireland—small design preferences can drastically alter long-term patient adherence and Quality-Adjusted Life Year (QALY) calculations. The insights inside demonstrate how to capture these preferences quantitatively, allowing you to arm your team with a powerful value story that protects your pricing strategy and proves invaluable during intensive HSE negotiations.
Whether you are designing clinical trials, formulating pricing structures, or preparing a reimbursement submission, this whitepaper provides a practical roadmap for the modern pharmaceutical commercial toolkit. Read the complete analysis to discover how to bridge the gap between clinical data and real-world value perception.
